Reduction in levels seen using an intact lipoprotein(a) assay and apolipoprotein(a)-based assay<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Nov. 25, 2024 (HealthDay News) — Muvalaplin reduces lipoprotein(a) levels, according to a study published online Nov. 20 in the Journal of the American Medical Association <\/em>to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.<\/p>\n Stephen J. Nicholls, M.B.B.S., Ph.D., from Monash University in Clayton, Australia, and colleagues examined the effect of muvalaplin on lipoprotein(a) levels and assessed safety and tolerability in a phase 2, placebo-controlled trial. A total of 233 participants with lipoprotein(a) concentrations of 175 nmol\/L or greater with atherosclerotic cardiovascular disease, diabetes, or familial hypercholesterolemia at 43 sites were randomly assigned to receive orally administered muvalaplin at dosages of 10, 60, or 240 mg\/day (34, 64, and 68 participants, respectively) or placebo (67 participants) for 12 weeks.<\/p>\n The researchers found that muvalaplin resulted in placebo-adjusted reductions of 47.6, 81.7, and 85.8 percent in lipoprotein(a) for the 10-, 60-, and 240-mg\/day dosages, respectively, using an intact lipoprotein(a) assay, and 40.4, 70.0, and 68.9 percent, respectively, using an apolipoprotein(a)-based assay. Dose-dependent reductions in apolipoprotein B were seen for 8.9, 13.1, and 16.1 percent at doses of 10, 60, and 240 mg\/day, respectively. There was no change noted in high-sensitivity C-reactive protein. Safety and tolerability concerns were not seen at any dose.<\/p>\n “Muvalaplin inhibits lipoprotein(a) assembly with oral delivery, with evidence of effective lipoprotein(a) lowering and a favorable safety and tolerability profile,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which manufactures muvalaplin and funded the study.<\/p>\n